长按二维码,关注官方公众号
QR Code for the Conference Website (Mobile)
Enter the applet sharing event using WeChat scan.
In the context of being part of ICH, the biopharmaceutical industry in China has entered a new era with emerging challenges: how to develop the next generation of innovative therapeutic biologics to stand out from the competition? How to speed up from R&D to regulatory submission with differentiated product pipelines (antibodies, therapeutic vaccines, cell and gene therapy products, virus products)?How to make compliance with regulatory requirements when making bioprocess improvement changes? How to accelerate the clinical development of innovative biopharma and biosimilars? What factors should be considered in the mass production and plant construction of biopharma?
As the most influential annual biopharma event in China, the 7th BioCon 2020 will be held on July 7-9 in CECIS-Shanghai, with higher speaker quality, deeper insights, cutting-edge regulation interpretation, and real technical case studies from leading biopharma players. Comprehensive topics will cover from drug discovery to IND, from the laboratory test to industrialization, from preclinical development to clinical development, from process development to commercial production, from NDA to commercial launch . The event aims to build a professional platform for regulatory discussions, technical exchanges, product displays, project cooperation from China and overseas, hence helping industry players to succeed in the fast growing Chinese biopharmaceutical industry!
Interpreting the latest guidelines of global regulations and China's new policies to help biopharma companies to navigate in the changing
regulatory environment
Focusing on the development of hot product portfolios -- the next generation of polyclonal antibodies, ADC, nano-antibodies, cell therapy, oncolytic viruses, recombinmant proteins and etc.
Sharing the best practices of global product submissions with multi-centerclinical trials worldwide
Analyzing the latest discoveries and achievements of combined therapy for cancer
Introducing the application of new antibody development platforms to improve R&D efficiency with lower cost
Discussing the optimized bioprocess changing paths and the supervision of post-process changing requirements
Exploring cost-effective biopharma plant design and construction in compliance with GMP requirements
BioCon China is dedicated to establishing a robust idea-exchanging and business-cooperating platform for global regulatory agencies, and worldwide leading biotech companies and Asian biopharmaceutical enterprises. In the previous activities, BioCon China has accumulated 4000+ global industrial participants, 320+ leading products, solution and service providers, and 450+ prominent speakers to join the annual grand events.
李宗海博士，科济药业创始人、董事会主席、首席执行官、首席科学官。
李宗海博士在生物制药领域有20余年工作经验，曾于2005年7月至2018年6月在上海市肿瘤研究所任职，并于该期间在上海市肿瘤研究所癌基因及相关基因国家重点实验室担任生物治疗研究组组长。
李宗海博士是CAR-T细胞免疫治疗领域的开拓者和领军人物之一，致力于为癌症患者开发创新疗法，带领团队开展了针对肝癌、胃癌、胰腺癌、肺鳞癌、胶母细胞瘤、多发性骨髓瘤、原发性浆细胞白血病等的临床研究。
